Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 14/20 | 0.71 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20983813 | 0.83 | ABHD6 (1.00) | ABHD6 | |
| SCHEMBL20983766 | 0.81 | ABHD6 (1.00) | ABHD6CARM1PRMT6PRMT1ACACB | |
| SCHEMBL20983768 | 0.81 | ABHD6 (1.00) | ABHD6CARM1PRMT6PRMT1ACACB | |
| SCHEMBL29421744 | 0.76 | ABHD6 (0.65) | ABHD6 | |
| SCHEMBL2119725 | 0.76 | ABHD6 (0.65) | ABHD6 | |
| SCHEMBL1550147 | 0.76 | ABHD6 (0.60) | ABHD6CARM1PRMT6PRMT1ACACB | |
| SCHEMBL29554819 | 0.76 | TMEM97 (0.58) | ABHD6 | |
| SCHEMBL4008584 | 0.74 | NOTUM (0.61) | ABHD6CARM1PRMT6PRMT1ACACB | |
| SCHEMBL772680 | 0.74 | ABHD6 (0.69) | ABHD6CARM1PRMT6PRMT1ACACB | |
| SCHEMBL16269157 | 0.74 | ABHD6 (0.55) | ABHD6CARM1PRMT6PRMT1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190152917-A1 | ABHD6 AND DUAL ABHD6/MGL INHIBITORS AND THEIR USES | MAKSCIENTIFIC, LLC | 2019-05-23 | — | — | US | claimed |
| US-10662159-B2 | ABHD6 and dual ABHD6/MGL inhibitors and their uses | MAKSCIENTIFIC, LLC (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190152917-A1 | ABHD6 AND DUAL ABHD6/MGL INHIBITORS AND THEIR USES | MAKSCIENTIFIC, LLC | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662159-B2 | ABHD6 and dual ABHD6/MGL inhibitors and their uses | ABHD6, FAAH, FAAH2 | ABHD6 1/4885CARM1 4550/4885PRMT6 903/4885 |
| US-20190152917-A1 | ABHD6 AND DUAL ABHD6/MGL INHIBITORS AND THEIR USES | ABHD6, FAAH, FAAH2 | ABHD6 1/4885CARM1 4550/4885PRMT6 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.